Form 4: Coherus Oncology Director Jill O'Donnell-Tormey Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Jill O'Donnell-Tormey was granted 112,000 stock options with an exercise price of $0.7904 per share, vesting fully on June 11, 2026.

Summary

• Jill O'Donnell-Tormey, a Director of Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these stock options is $0.7904 per share.
• The options will vest and become exercisable as to 100% of the total number of shares on the one-year anniversary of June 11, 2025, which is June 11, 2026.
• Vesting is contingent upon Ms. O'Donnell-Tormey's continued service relationship with Coherus Oncology, Inc. on the vesting date.
• The expiration date for these stock options is June 12, 2035.
• Following this reported transaction, Ms. O'Donnell-Tormey beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It is a routine compensation event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages the director's continued service and commitment to the company.

Future Outlook

The stock options granted to Director Jill O'Donnell-Tormey are set to vest fully on June 11, 2026, contingent on her continued service, indicating a future milestone for her equity compensation.

Industry Context

This Form 4 filing represents a routine insider transaction related to director compensation, common across publicly traded companies in all industries, including the biotechnology and oncology sectors. Such grants are standard practice to incentivize and retain key personnel.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive step towards aligning management and board interests with shareholder value, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The 112,000 stock options are scheduled to vest on June 11, 2026, provided Jill O'Donnell-Tormey remains in service with Coherus Oncology, Inc.

Key Dates

Keywords

Coherus Oncology, CHRS, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation